Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tae Ho Hwang

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyJeong Heo, Caroline J Breitbach, Anne Moon, et al.
Cancer Research|February 9, 2013
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humansCaroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
Nature Medicine|February 12, 2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerJeong Heo, Tony Reid, Leyo Ruo, et al.
Nature|September 3, 2011
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansCaroline J Breitbach, James Burke, Derek Jonker, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyJeong Heo, Caroline J Breitbach, Anne Moon, et al.
Cancer Research|February 9, 2013
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humansCaroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 9, 2014
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityHerbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, et al.
Nature Medicine|February 12, 2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerJeong Heo, Tony Reid, Leyo Ruo, et al.
Nature|September 3, 2011
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansCaroline J Breitbach, James Burke, Derek Jonker, et al.
Pageof 6